With $260m in the bank and Teva funding trails on a number of their products, I dont think the financial position is weak at all. In fact, it is the cash position and the backing of a large pharma which justifies its price.
I suspect we will soon see another pharma come to the p[arty and fund the diabetes trials.
So, I am very curious as to why you would suggest the financial position to be weak.
In my view, the greatest value MSB have is their gobal stem cell patent which is why the likes of Cephalon and Teva are willing to fund and hold a stake in the group.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.010(0.61%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.64 | $5.790M | 3.482M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 460 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 67181 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |